News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
246,797 Results
Type
Article (17367)
Company Profile (40)
Press Release (229390)
Section
Business (66436)
Career Advice (170)
Deals (10323)
Drug Delivery (27)
Drug Development (76097)
Employer Resources (12)
FDA (5722)
Job Trends (5403)
News (150693)
Policy (10519)
Tag
Academia (820)
Alliances (17486)
ALS (57)
Alzheimer's disease (949)
Antibody-drug conjugate (ADC) (82)
Approvals (5688)
Artificial intelligence (59)
Bankruptcy (74)
Best Places to Work (4678)
Breast cancer (167)
Cancer (1236)
Cardiovascular disease (90)
Career advice (151)
CAR-T (88)
Cell therapy (222)
Clinical research (65502)
Collaboration (275)
Compensation (100)
COVID-19 (1645)
C-suite (66)
Cystic fibrosis (65)
Data (1168)
Diabetes (105)
Diagnostics (1951)
Earnings (28005)
Events (37234)
Executive appointments (227)
FDA (6149)
Funding (257)
Gene editing (65)
Gene therapy (142)
GLP-1 (493)
Government (1458)
Healthcare (5355)
Immunology and inflammation (60)
Infectious disease (1709)
Inflammatory bowel disease (78)
IPO (5577)
Job creations (990)
Job search strategy (130)
Layoffs (254)
Legal (830)
Lung cancer (208)
Lymphoma (94)
Manufacturing (83)
Medical device (1454)
Medtech (1456)
Mergers & acquisitions (4867)
Metabolic disorders (338)
Neurodegenerative disease (63)
Neuroscience (1242)
NextGen: Class of 2025 (1395)
Non-profit (672)
Northern California (1138)
Obesity (193)
Opinion (89)
Parkinson's disease (77)
People (18148)
Phase I (20456)
Phase II (29710)
Phase III (22190)
Pipeline (498)
Postmarket research (975)
Preclinical (4352)
Radiopharmaceuticals (144)
Rare diseases (217)
Real estate (1472)
Regulatory (9165)
Research institute (1010)
Southern California (969)
Startups (1257)
United States (8223)
Vaccines (394)
Weight loss (138)
Date
Today (54)
Last 7 days (195)
Last 30 days (998)
Last 365 days (18316)
2025 (893)
2024 (18474)
2023 (20439)
2022 (23305)
2021 (24154)
2020 (20750)
2019 (14709)
2018 (11199)
2017 (13805)
2016 (12006)
2015 (14147)
2014 (9848)
2013 (7283)
2012 (7629)
2011 (8039)
2010 (7374)
Location
Africa (169)
Asia (17356)
Australia (3133)
California (2463)
Canada (675)
China (243)
Connecticut (105)
Europe (39606)
Florida (261)
Georgia (62)
Illinois (119)
Indiana (112)
Japan (76)
Maryland (290)
Massachusetts (1649)
Minnesota (93)
New Jersey (653)
New York (660)
North Carolina (433)
Northern California (1138)
Ohio (69)
Pennsylvania (476)
South America (225)
Southern California (969)
Texas (283)
Washington State (208)
246,797 Results for "phase genomics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ecotone Achieves Breakthrough in Human Genome Understanding with Novel AI Technology
AI-Powered Genomic Mapping Could Revolutionize Treatment of Rare Genetic Diseases
January 16, 2025
·
1 min read
Business
Phase Genomics Announces Appointment of David Shoultz as First Chief Business Officer
October 9, 2024
·
2 min read
BioForest
Phase Genomics Announces Funding to Accelerate Discovery of New Lysin-Based Precision Antimicrobials
Phase Genomics, Inc. today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform.
March 5, 2024
·
3 min read
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
·
1 min read
·
Kate Goodwin
Obesity
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s prior projections for the therapy. Meanwhile, Eli Lilly’s stock rose on the news.
December 20, 2024
·
3 min read
·
Tristan Manalac
Immunology and inflammation
Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data
The discontinuation caps off a turbulent development path for izokibep, which in September 2023 produced disappointing results from Phase IIb/III study in hidradenitis suppurativa that was found to have had dosing errors.
December 11, 2024
·
2 min read
·
Tristan Manalac
Business
Dovetail Genomics and AGRF Announce Transformative Partnership Set to Advance Genomic Research in Australasia
Dovetail Genomics, a pioneering leader in the development of genomic solutions, announced a new strategic partnership with Australian Genome Research Facility.
June 24, 2024
·
4 min read
Neurodegenerative disease
Biohaven Drug Misses in Phase III for SMA, Will Be Tested in Obesity
While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked reduction in body fat. Biohaven plans to launch a Phase II trial in obesity by the end of the year.
November 25, 2024
·
2 min read
·
Tristan Manalac
BioForest
Phase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid Leukemia
Phase Genomics, Inc., a global innovator for industry-leading genomic solutions, today announced the presentation of new data from the proximity ligation sequencing-based OncoTerra cytogenomics platform on the leading-edge AVITI next-generation sequencing system.
November 17, 2023
·
3 min read
Press Releases
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
--Six sites across the U.S. are now engaged in Phase1b study
November 19, 2024
·
5 min read
1 of 24,680
Next
